| Oct 30 |
ITCI Q3 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales
|
| Oct 30 |
Novartis’ Scemblix gains FDA approval for leukaemia
|
| Oct 30 |
Novartis: It's Not Too Late To Buy This Dividend Stock Now
|
| Oct 30 |
Novartis Reports Strong Q3 Growth and Raises Guidance
|
| Oct 30 |
Novartis AG (NVS) Q3 2024 Earnings Call Highlights: Record Cash Flow and Robust Sales Growth
|
| Oct 29 |
Novartis: Strong Financials, But Market Skepticism Persists Amid Pipeline Concerns
|
| Oct 29 |
Novartis wins first-line chronic myeloid leukemia indication for Scemblix
|
| Oct 29 |
Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile
|
| Oct 29 |
Novartis Stock Dives on $800 Million Write-Down
|
| Oct 29 |
Novartis Ag (NVS) Q3 2024 Earnings Call Transcript
|
